IceCure VP discloses options and RSU holdings

IceCure Medical Ltd. VP of Human Resources Dotan Merav Nir filed a Form 3 disclosing existing equity holdings in the company.

Rhea-AI Filing Summary

IceCure Medical Ltd. VP of Human Resources Dotan Merav Nir filed a Form 3 disclosing existing equity holdings in the company. The filing shows direct ownership of 68,814 ordinary shares, made up of 500 shares and 68,314 unvested restricted stock units granted in 2024, 2025, and 2026 as of March 18, 2026.

Nir also holds share options over 80,668 ordinary shares at an exercise price of $3.64 per share fully vested and expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 27,283 options at $0.92 expiring in 2034. The Form 3 records these positions only, with no reported purchases or sales.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Dotan Merav Nir

Role VP, Human Resources

Type	Security	Shares	Price	Value
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Share option (right to buy) — 148,656 contracts (Direct); Ordinary shares — 68,814 shares (Direct)

Footnotes (6)

1. F1. Represents (i) 500 ordinary shares, (ii) 22,736 restricted stock units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (iii) 32,386 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 13,192 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
2. F2. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.
3. F3. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
4. F4. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.
5. F5. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
6. F6. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 10,231 are vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IceCure Medical (ICCM) Form 3 filing show for Dotan Merav Nir?

The Form 3 shows Dotan Merav Nir’s existing equity stake in IceCure Medical. It details direct ownership of 68,814 ordinary shares plus multiple option grants and unvested RSUs, all as of March 18, 2026, with no new trades reported.

How many IceCure Medical (ICCM) ordinary shares does Dotan Merav Nir hold?

Dotan Merav Nir holds 68,814 ordinary shares of IceCure Medical. This total consists of 500 shares and 68,314 unvested restricted stock units granted across 2024, 2025, and 2026, all of which remained unvested as of March 18, 2026.

What stock options in IceCure Medical (ICCM) are reported for Dotan Merav Nir?

The filing lists three option grants over IceCure ordinary shares. These cover 80,668 shares at $3.64, 40,705 shares at $1.51, and 27,283 shares at $0.92, expiring in 2032, 2033, and 2034, respectively, with varying vesting levels disclosed.

Were there any IceCure Medical (ICCM) share purchases or sales in this Form 3?

No purchases or sales are reported in this Form 3. All entries are classified as holdings, and the transaction summary shows zero buy or sell transactions, indicating the filing simply records existing ownership positions as of March 18, 2026.

What restricted stock units (RSUs) are reported for IceCure Medical (ICCM) VP Dotan Merav Nir?

The filing details three RSU grants: 22,736 RSUs from July 2, 2024, 32,386 RSUs from November 5, 2025, and 13,192 RSUs from March 16, 2026. All these RSUs remained unvested as of March 18, 2026, with standard 25% cliff and quarterly vesting thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dotan Merav Nir

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Human Resources

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	68,814(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	(2)	01/12/2032	Ordinary shares	80,668	$3.64(3)	D
Share option (right to buy)	(4)	02/19/2033	Ordinary shares	40,705	$1.51(5)	D
Share option (right to buy)	(6)	07/02/2034	Ordinary shares	27,283	$0.92	D

Explanation of Responses:

1. Represents (i) 500 ordinary shares, (ii) 22,736 restricted stock units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, (iii) 32,386 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 13,192 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

2. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.

3. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

4. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 30,528 options are vested.

5. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

6. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 10,231 are vested.

	/s/ Merav Nir Dotan	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)